NBIO - Nascent Biotech shares fall ~16% on track for seventh session of losses in eight

• Shares of OTC listed Nascent Biotech ( OTCQB:NBIO ) fell 16.1% to $0.26 in Tuesday morning trading, continuing a recent weak trend for the stock which has seen it post losses in six of its last seven sessions .
• NBIO shares posted a five-day losing streak last week, including a 21.3% plunge on Sept. 28.
• The company earlier in the day said it had enrolled the first patient of the fifth and final cohort of its phase 1 trial evaluating antibody Pritumumab for the treatment of brain cancers.
• The company had completed dosing patients in the fourth cohort of the trial last month.
• NBIO said it would prepare data for submission to the U.S. FDA in preparation for phase 2 research following completion of dosing in the fifth cohort.

For further details see: